MTOR and esophageal squamous cell carcinoma: For example, it was reported that 11.5% of the tumors from ESCC patients harbored PIK3CA mutations20 and that the aberrant activation of mTOR occurred in 69.5% and 25% of ESCC in Japanese patients11 and Caucasian patients in the Netherlands21, respectively.